on GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics Launches Newsletter for Retail Investors
Paris, France, July 11, 2024 – GenSight Biologics (Euronext: SIGHT), a biopharma company specializing in gene therapies for retinal neurodegenerative diseases, has announced the release of its first newsletter for retail investors. The quarterly newsletter, available in French, will be accessible on the company's website and through subscription.
Laurence Rodriguez, CEO of GenSight Biologics, emphasized the importance of this new communication channel, aimed at providing updates and detailed insights to their investor base. Rodriguez expressed gratitude towards the investors for their continued support.
The debut issue includes a letter from the CEO, a summary of recent news, a calendar of upcoming conferences, recognition of co-founders' award in optogenetics, a look at LUMEVOQ® manufacturing, and key financial figures.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENSIGHT BIOLOGICS S.A. news